RM

Ritu Malik

Active Director Director DIN 09336193
DIN 09336193 First appointment Sep 2021 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Sep 2021
Shareholding value •••• Premium profile

About Ritu Malik

Data last updated:

Ritu Malik is a Director at Araqure Pharmaceuticals Private Limited (since 2021). The company operates in Chemicals. Araqure Pharmaceuticals Private Limited reported revenue of ₹1.27 Cr (FY 2024).

DIN 09336193
Primary Designation Director
Industry Chemicals
First Appointment 27 Sep 2021
Oldest Company Age 5 yrs
Largest company Araqure Pharmaceuticals Private Limited · ₹1.27 Cr (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director27 Sep 20212021₹1.27 Cr (FY 2024)Active

Board colleagues of Ritu Malik

NameDINCompanyDesignation
Piyush Malik09336152Araqure Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Araqure Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Ritu Malik

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ritu Malik

Ritu Malik currently holds 1 directorship: Araqure Pharmaceuticals Private Limited (Director, since 27 Sep 2021, revenue ₹1.27 Cr (FY 2024)).

Ritu Malik was first appointed on 27 Sep 2021 as Director at Araqure Pharmaceuticals Private Limited.

The current boards of Ritu Malik's companies include Piyush Malik (Araqure Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available